CoChat

Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans

Open access
Grimm, Hans Peter, Schumacher, Vanessa, Schäfer, Martin, Imhof-Jung, Sabine, Freskgård, Per-Ola, Brady, Kevin, Hofmann, Carsten, Rüger, Petra, Schlothauer, Tilman, Göpfert, Ulrich, Hartl, Maximilian, Rottach, Sylvia, Zwick, Adrian, Seger, Shanon, Neff, Rachel, Niewoehner, Jens, Janssen, Niels · 2023 · mAbs
Cited by 169

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

There are few treatments that slow neurodegeneration in Alzheimer’s disease (AD), and while therapeutic antibodies are being investigated in clinical trials for AD treatment, their access to the central nervous system is restricted by the blood–brain barrier. This study investigates a bispecific modular fusion protein composed of gantenerumab, a fully human monoclonal anti- amyloid-beta (Aβ) antibody under investigation for AD treatment, with a human transferrin receptor 1-directed Brainshuttle™ module (trontinemab; RG6102, INN trontinemab). In vitro, trontinemab showed a similar binding affinity to fibrillar Aβ40 and Aβ plaques in human AD brain sections to gantenerumab. A single intravenous administration of trontinemab (10 mg/kg) or gantenerumab (20 mg/kg) to non-human primates (NHPs, Macaca fascicularis), was well tolerated in both groups. Immunohistochemistry indicated increased trontinemab uptake into the brain endothelial cell layer and parenchyma, and more homogeneous distribution, compared with gantenerumab. Brain and plasma pharmacokinetic (PK) parameters for trontinemab were estimated by nonlinear mixed-effects modeling with correction for tissue residual blood, indicating a 4–18-fold increase in brain exposure. A previously developed clinical PK/pharmacodynamic model of gantenerumab was adapted to include a brain compartment as a driver of plaque removal and linked to the allometrically scaled above model from NHP. The new brain exposure-based model was used to predict trontinemab dosing regimens for effective amyloid reduction. Simulations from these models were used to inform dosing of trontinemab in the first-in-human clinical trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/19420862.2023.2261509

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 169

Metadata

Authors
Grimm, H. P., Schumacher, V., Schäfer, M., Imhof-Jung, S., Freskgård, P.-O., Brady, K., Hofmann, C., Rüger, P., Schlothauer, T., Göpfert, U., Hartl, M., Rottach, S., Zwick, A., Seger, S., Neff, R., Niewoehner, J., & Janssen, N.
Venue
mAbs
Published
2023-10-12
Volume
15
Issue
1
Pages
2261509-2261509
ISSN
  • 1942-0862 (ISSN-L)
  • 1942-0870
OpenAlex
W4387564410
Cited by
169
References
15
FWCI
24.47
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans. https://app.cochat.ai/papers/10.1080/19420862.2023.2261509
The paper
Grimm, H. P., Schumacher, V., Schäfer, M., Imhof-Jung, S., Freskgård, P.-O., Brady, K., Hofmann, C., Rüger, P., Schlothauer, T., Göpfert, U., Hartl, M., Rottach, S., Zwick, A., Seger, S., Neff, R., Niewoehner, J., & Janssen, N. (2023). Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans. mAbs. https://doi.org/10.1080/19420862.2023.2261509

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.